Document is current
Any future updates will be listed below
-
Authors
van den Bergh, J.P.
Szulc, P.
Cheung, A.M.
Bouxsein, M.
Engelke, K.
Chapurlat, R.
- License Information
-
More Information
Article History
Received: 14 December 2020
Accepted: 6 May 2021
First Online: 22 May 2021
Declarations
:
: Joop van den Bergh revceived research funding from Amgen, Eli Lilly, and UCB. Angela M. Cheung has received consultant fees from Amgen, Alexion, and Regeneron; University Health Network has received research funding from Ipsen, Mereo, and Regeneron for conduct of clinical trials. Klaus Engelke is part time employee of Bioclinica, Inc. Roland Chapurlat has received research funding from Amgen and UCB as well as consultant or speaking fees from Amgen, UCB, Kyowa-Kirin, and Eli Lilly. Pawel Szulc has no disclosures. Mary Bouxsein has no disclosures.
